Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Alkermes plc
The Washington Legal Foundation says California’s appeals court should see Ethicon’s statements about pelvic mesh as protected scientific speech.
ACIP will get a chance to further restrict and tailor the US booster plan for COVID vaccinations. Among other things, CDC's advisors may have to define what constitutes being at high risk of severe COVID-19 post-primary vaccination, occupations at high risk of COVID exposure, and whether people who didn’t receive Pfizer’s primary vaccine series could get the company’s mRNA booster shot.
Adagrasib may carve out a niche as the superior drug in colorectal cancer, but lung cancer – where Lumakras already is approved – is a larger market where Amgen has a big lead.
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
- Other Names / Subsidiaries
- Rodin Therapeutics, Inc.